Equatorial GuineaTuberculosis profile
Population  2014 <1 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.054 (0.033–0.081) 6.6 (4–9.9)
Mortality (HIV+TB only) 0.049 (0.033–0.069) 6 (4–8.4)
Prevalence  (includes HIV+TB) 1.1 (0.56–1.9) 140 (69–236)
Incidence  (includes HIV+TB) 1.3 (1.2–1.5) 162 (142–184)
Incidence (HIV+TB only) 0.67 (0.52–0.84) 82 (64–102)
         
Case detection, all forms (%) 88 (77–100)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.7 (0.9–2.6) 13 (11–15)
MDR-TB cases among notified pulmonary
TB cases
17 (9–25) 12 (10–14)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 700   41
Pulmonary, clinically diagnosed 280   3
Extrapulmonary 142   0
       
Total new and relapse 1 166    
Previously treated, excluding relapses 47    
Total cases notified 1 213    
Among 1 024 new and relapse cases:
58 (6%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 2 (<1%) 5 (5%) 7
Laboratory-confirmed RR-/MDR-TB cases     7
Patients started on MDR-TB treatment ***     4
TB/HIV 2014 Number (%)
TB patients with known HIV status 732 (60)
HIV-positive TB patients 293 (40)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART) 266 (91)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (62) 1 152
Previously treated cases, excluding relapse, registered in 2013 (53) 59
HIV-positive TB cases, all types, registered in 2013 (57) 259
RR-/MDR-TB cases started on second-line treatment in 2012    
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.0
Culture (per 5 million population) 0
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions)  
% Funded domestically  
% Funded internationally  
% Unfunded  
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-30 Data: www.who.int/tb/data